Premium
Quantification of myrislignan in rat plasma by solid‐phase extraction and reversed‐phase high‐performance liquid chromatography
Author(s) -
Li Fei,
Yang Xiuwei
Publication year - 2008
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.975
Subject(s) - chromatography , chemistry , high performance liquid chromatography , extraction (chemistry) , analyte , solid phase extraction , detection limit , phase (matter) , plasma , pharmacokinetics , analytical chemistry (journal) , medicine , physics , organic chemistry , quantum mechanics
A rapid and simple reversed‐phase high‐performance liquid chromatographic (RP‐HPLC) method has been developed for determination of myrislignan in rat plasma after intravenous administration. The analytes extracted from plasma samples by solid‐phase extraction were successfully carried out on a Diamonsil™ ODS C 18 column (250 × 4.6 mm i.d., 5 µm) with an RP 18 guard column (8 × 4.6 mm i.d., 5 µm) and a mobile phase of MeOH–H 2 O (4:1, v/v). The UV detector was set at a single wavelength of 270 nm. The linear ranges of the standard curves were 0.5–30.0 µg/mL with the correlation coefficients greater than 0.9992. The lower limits of detection and quantification were 0.1 and 0.3 µg/mL for myrislignan. Intra‐ and inter‐day precisions were 2.4–7.5 and 1.3–5.7%, respectively. The extraction recovery from plasma was more than 90%. This assay method has been successfully used to study the pharmacokinetics of myrislignan in rats. Copyright © 2008 John Wiley & Sons, Ltd.